Journal article
Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population
Talita Duarte-Salles, Sandeep Misra, Magdalena Stepien, Amelie Plymoth, David Muller, Kim Overvad, Anja Olsen, Anne Tjonneland, Laura Baglietto, Gianluca Severi, Marie-Christine Boutron-Ruault, Renee Turzanski-Fortner, Rudolf Kaaks, Heiner Boeing, Krasimira Aleksandrova, Antonia Trichopoulou, Pagona Lagiou, Christina Bamia, Valeria Pala, Domenico Palli Show all
Cancer Prevention Research | AMER ASSOC CANCER RESEARCH | Published : 2016
Abstract
We previously identified osteopontin (OPN) as a promising marker for the early detection of hepatocellular carcinoma (HCC). In this study, we investigated the association between prediagnostic circulating OPN levels and HCC incidence in a large population-based cohort. A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each case was matched to two controls and OPN levels were measured in baseline plasma samples. Viral hepatitis, liver function, and α-fetoprotein (AFP) tests were also conducted. Conditional logistic regression models were used to c..
View full abstractGrants
Awarded by NIH
Awarded by French National Cancer Institute (Institut National du Cancer; INCA)
Awarded by European Research Council (ERC) (Norway)
Awarded by Regional Government of Andalucia (Spain)
Awarded by Regional Government of Navarra (Spain)
Awarded by ISCIII RETIC (Spain)
Awarded by Regional Government of Basque Country (Spain)
Awarded by Regional Government of Murcia (Spain)
Awarded by NATIONAL CANCER INSTITUTE
Awarded by Cancer Research UK
Awarded by Medical Research Council
Awarded by National Institute for Health Research
Funding Acknowledgements
This work was supported by NIH R01 CA120719 to L. Beretta and by the French National Cancer Institute (Institut National du Cancer; INCA) grant number 2009-139 to M. Jenab. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer; Institut Gustave Roussy; Mutuelle Generale de l'Education Nationale, and Institut National de la Sante et de la Recherche Medicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ); and Federal Ministry of Education and Research (Germany); Hellenic Health Foundation (Greece); Italian Association for Research on Cancer (AIRC); National Research Council; and AIRE-ONLUS Ragusa, AVIS Ragusa, Sicilian Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS); Netherlands Cancer Registry (NKR); LK Research Funds; Dutch Prevention Funds; Dutch ZON (ZorgOnderzoek Nederland); World Cancer Research Fund (WCRF); and Statistics Netherlands (the Netherlands); European Research Council (ERC; grant number ERC-2009-AdG 232997) and Nordforsk; and Nordic Center of Excellence Programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS); Regional Governments of Andalucia, Asturias, Basque Country, Murcia (No. 6236) and Navarra; and ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society; Swedish Scientific Council; and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research UK; Medical Research Council; Stroke Association; British Heart Foundation; Department of Health; Food Standards Agency; and Wellcome Trust (UK).